As bluebird projects more commercial demand, the biotech continues to seek cash

Bluebird bio reported that 17 people with sickle cell disease have started the process of receiving its gene therapy Lyfgenia. Bluebird said in its third-quarter earnings Thursday that it recognized revenue ...